LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

0.35 2.94

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.33

Max

0.35

Põhinäitajad
By Trading Economics
Sissetulek	983K -47M
Müük	505K 14M
Kasumimarginaal	-342.329
Töötajad	161
EBITDA	-346K -46M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+1261.76% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-26M 79M
Eelmine avamishind	-2.59
Eelmine sulgemishind	0.35

Uudiste sentiment

By Acuity

79%

21%

312 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2026, 22:54 UTC

Tulu

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13. mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13. mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13. mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13. mai 2026, 23:17 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13. mai 2026, 23:16 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13. mai 2026, 23:15 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13. mai 2026, 23:14 UTC

Tulu

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13. mai 2026, 23:02 UTC

Market Talk

Tulu

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13. mai 2026, 22:59 UTC

Market Talk

Tulu

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13. mai 2026, 22:24 UTC

Tulu

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Organic Revenue Growth 25%>XRO.AU

13. mai 2026, 22:23 UTC

Tulu

Xero FY International Revenue Growth 47%>XRO.AU

13. mai 2026, 22:22 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13. mai 2026, 22:19 UTC

Tulu

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13. mai 2026, 22:19 UTC

Tulu

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13. mai 2026, 22:18 UTC

Tulu

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13. mai 2026, 22:16 UTC

Tulu

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13. mai 2026, 22:15 UTC

Tulu

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13. mai 2026, 22:13 UTC

Tulu

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13. mai 2026, 22:12 UTC

Tulu

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13. mai 2026, 22:11 UTC

Tulu

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13. mai 2026, 22:11 UTC

Tulu

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13. mai 2026, 22:10 UTC

Tulu

Xero Did Not Declare a Dividend>XRO.AU

13. mai 2026, 22:10 UTC

Tulu

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13. mai 2026, 22:09 UTC

Tulu

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13. mai 2026, 22:00 UTC

Tulu

Cisco to Shed Jobs for All-In AI Push -- Update

13. mai 2026, 21:11 UTC

Tulu

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

1261.76% tõus

12 kuu keskmine prognoos

Keskmine 4.63 USD 1261.76%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

312 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.